4.4 Review

Metabolomics in pancreatic cancer biomarkers research

Journal

MEDICAL ONCOLOGY
Volume 33, Issue 12, Pages -

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12032-016-0853-6

Keywords

Metabolomics; Metabolome; Biomarkers; Pancreatic cancer

Categories

Ask authors/readers for more resources

Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15-20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Non-Coding RNAs in Glioma

Ryte Rynkeviciene, Julija Simiene, Egle Strainiene, Vaidotas Stankevicius, Jurgita Usinskiene, Edita Miseikyte Kaubriene, Ingrida Meskinyte, Jonas Cicenas, Kestutis Suziedelis

CANCERS (2019)

Article Oncology

Towards a Personalized Approach in Pancreatic Cancer Diagnostics Through Plasma Amino Acid Analysis

Jaroslav Tumas, Inga Baskirova, Tomas Petrenas, Jolita Norkuniene, Kestutis Strupas, Audrius Sileikis

ANTICANCER RESEARCH (2019)

Article Oncology

Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells

Dalius Kuciauskas, Nadezda Dreize, Marija Ger, Algirdas Kaupinis, Kristijonas Zemaitis, Vaidotas Stankevicius, Kestutis Suziedelis, Jonas Cicenas, Lee M. Graves, Mindaugas Valius

CANCERS (2019)

Article Medicine, General & Internal

Gallstone Ileus: Management and Clinical Outcomes

Matas Jakubauskas, Raminta Luksaite, Audrius Sileikis, Kestutis Strupas, Tomas Poskus

MEDICINA-LITHUANIA (2019)

Article Nutrition & Dietetics

Nutritional and immune impairments and their effects on outcomes in early pancreatic cancer patients undergoing pancreatoduodenectomy

Jaroslav Tumas, Birute Tumiene, Jolita Jurkeviciene, Eugenijus Jasiunas, Audrius Sileikis

CLINICAL NUTRITION (2020)

Article Medicine, General & Internal

Effects of Immunonutrition on Comprehensive Complication Index in Patients Undergoing Pancreatoduodenectomy

Jaroslav Tumas, Eugenijus Jasiunas, Kestutis Strupas, Audrius Sileikis

MEDICINA-LITHUANIA (2020)

Article Oncology

Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26

Egle Zalyte, Veronika Dedonyte, Benediktas Kurlinkus, Audrius Sileikis, Peter Schemmer, Mindaugas Valius

Summary: The newly established pancreatic cancer cell line Capan-26 exhibits unique characteristics such as long cell doubling time, specific marker expression, mutations, and high sensitivity, making it a valuable tool for studying the mechanisms of pancreatic cancer.

ANTICANCER RESEARCH (2021)

Editorial Material Oncology

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020

Jonas Cicenas, Asta Raciene

CANCERS (2021)

Article Biology

CEACAM6's Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6's Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA

Benediktas Kurlinkus, Marija Ger, Algirdas Kaupinis, Eugenijus Jasiunas, Mindaugas Valius, Audrius Sileikis

Summary: This study identified CEACAM6 as a promising new biomarker for pancreatic cancer, with significant prognostic value and prediction of chemoresistance properties, enabling the improvement of individualised approaches to patients with this disease.

LIFE-BASEL (2021)

Article Oncology

The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)

Skaiste Tulyte, Dainius Characiejus, Reda Matuzeviciene, Ausra Janiulioniene, Mantas Radzevicius, Tadas Zvirblis, Audrius Sileikis

Summary: This study evaluated the changes in circulating lymphocytes in patients with pancreatic ductal adenocarcinoma (PDAC) and found significant alterations in cell counts during treatment.

ANTICANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Starvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state

Egle Zalyte, Jonas Cicenas

Summary: Pancreatic cancer is a highly metastatic and therapy-resistant disease. This study explores a novel approach to kill pancreatic cancer cells by combining starvation with ferroptosis induction. The results indicate that the ERK1/2 and JNK signaling pathways, as well as the transition between epithelial and mesenchymal states, mediate sensitivity to ferroptosis in starved pancreatic cancer cells.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2022)

Article Medicine, General & Internal

Enterocutaneous Fistula: Open Repair after Unsuccessful Stenting-A Case Report

Valerija Mosenko, Saulius Jurevicius, Audrius Sileikis

Summary: Enterocutaneous fistula is an abnormal connection between the gastrointestinal tract and the skin, usually a complication of gastrointestinal surgery. The use of self-expanding metal stents (SEMS) to cover the fistula is a treatment method, but its application in small bowel ECF is still debated.

MEDICINA-LITHUANIA (2022)

Article Surgery

Postcholecystectomy bile duct injuries: evolution of surgical treatment

Audrius Sileikis, Ruta Zulpaite, Aukse Sileikyte, Martynas Luksta

POLISH JOURNAL OF SURGERY (2019)

Meeting Abstract Oncology

Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study

S. Tulyte, A. Sileikis, I. Tarnulyte, A. Ranceva, D. Characiejus, R. Matuzeviciene, A. Janiulioniene, T. Zvirblis

ANNALS OF ONCOLOGY (2019)

No Data Available